Musculoskeletal ultrasound to assess therapeutic effects of novel antirheumatic therapies in Psoriatic Arthritis

Musculoskeletal ultrasound to assess therapeutic effects of novel antirheumatic therapies in Psoriatic Arthritis - MSUS PsA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46720

Enrollment

Registered

2018-01-23

Start date

2018-05-22

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory arthritis psoriatic arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years or older - Active psoriatic arthritis, defined as *2 swollen and *2 tender joints - Starting with apremilast, secukinumab or anti-TNF therapy

Exclusion criteria

Exclusion criteria: - Other active concomitant musculoskeletal disease

Design outcomes

Primary

Measure	Time frame
The main outcomes of the study are the early ultrasound findings (baseline. week 2 and week 4) and the clinical therapeutic response to apremilast and secukinumab at 24 weeks	—

Secondary

Measure	Time frame
Secondary outcomes of the study are ultrasound findings and clinical assessments at all time points.	—

Countries

Netherlands

Outcome results